Figure 4

In vitro selection of R5 HIV variants in head-to-head competitions in direct and DC-SIGN-mediated infections. Competition assays were set-up with (a) inter-patient mixed chronic phase and end-stage R5 isolates from patients R and G, respectively and with (b) intra-patient mixed chronic AS and end-stage AIDS R5 isolates from patient J. Replicating viruses were identified by V2 region sequencing and presented percentage were calculated from ten to twelve parallel infections.